



## Alzinova interviewed by Redeye in connection with World Alzheimer's Day

**Alzinova AB (publ) (FN STO: ALZ), announces today, on World Alzheimer's Day, that CEO Kristina Torfgård has been interviewed by Redeye about Alzinova's recent progress.**

Today, September 21, is World Alzheimer's Day, which aims to draw attention to and raise awareness of Alzheimer's disease. In connection with World Alzheimer's Day, Alzinova's CEO Kristina Torfgård has made an interview with Redeye about the Company's latest progress and development in Alzheimer's research.

During the interview, Kristina Torfgård shared Alzinova's latest progress in the development of the Company's drug candidates ALZ-101 and ALZ-201 and told us more about the regulatory interactions with the FDA and EMA, the recent collaboration agreement with the leading peptide producer Polypeptide and the way forward for Alzinova.

The interview is available at Alzinova's website under presentations: [Link to the interview](#)

### **About World Alzheimer's Day**

World Alzheimer's Day is a worldwide event that takes place every year on September 21 and aims to raise awareness of Alzheimer's disease and the impact it has on millions of people worldwide. The theme for this year is "never too early, never too late" which aims to draw attention to the risk factors and potential preventive measures for Alzheimer's disease. Alzinova is determined to do its part to fight this disease and work towards a future without Alzheimer's.

### **For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*



### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Alzinova interviewed by Redeye in connection with World Alzheimer's Day**